A comprehensive view of eli lilly & co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
High demand for injectable weight-loss drugs has led to supply issues, with most varieties listed in short supply by the FDA; Eli Lilly reports shortages of its Zepbound and Mounjaro could last until 2025
Published:
April 19, 2024
by CBS - 12 WJTV (Jackson, MS)
|
Eli Lilly and plaintiffs abandon proposed US$13.5M settlement regarding alleged overpricing of insulin; the move follows a court ruling against certifying specific state-classes in the case
Published:
April 17, 2024
by FiercePharma
|
GlobalData: Eli Lilly set to reshape pharmaceutical landscape with obesity and Alzheimer's treatments, Mounjaro and donanemab; both drugs poised to beat market expectations, with Mounjaro's sales poised to reach US$34B in 2029, more than double Wegovy's
Published:
April 17, 2024
by GlobalData Plc
|
INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "PEPTIDES FOR INCRETIN SYNTHESIS"
Published:
April 17, 2024
by U.S. Fed News
|
INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "METHODS OF TREATING FATIGUE IN ULCERATIVE COLITIS"
Published:
April 17, 2024
by U.S. Fed News
|
Ask us about our Health Care Sector market view